Agenus Inc.
Clinical trials sponsored by Agenus Inc., explained in plain language.
A biotech developing immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to shrink Hard-to-Treat colorectal tumors Results expected Sep 2027 (estimated) May already have reported ↗
-
Desperate cancer patients get early access to promising drug combo
Disease control Expanded accessThis program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…
Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Cancer patients who responded to experimental immunotherapy can now continue treatment
Disease control Expanded accessThis expanded access program offers balstilimab, alone or with zalifrelimab, to cancer patients who previously received these drugs in a clinical trial and saw benefit. The goal is to allow continued treatment for those who wish to stay on therapy. Only patients who completed the…
Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC